BioStock: Spago’s phase I/IIa cancer trial progressing steadily

The positive momentum for Spago Nanomedical carries over into 2024 as the company announces continued progress with its Tumorad phase I/IIa trial. The independent data monitoring committee has recommended a dose escalation with the company’s radiopharmaceutical drug candidate 177Lu-SN201 for the treatment of advanced cancer.

Read the article at biostock.se:

Spago’s phase I/IIa cancer trial progressing steadily - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/